Need help finding what you are looking for?
Contact Us
PUBLISHER: FirstWord Group | PRODUCT CODE: 1355805
PUBLISHER: FirstWord Group | PRODUCT CODE: 1355805
Non-Hodgkin Lymphoma - KOL Insight
PUBLISHED:
PAGES:
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Bispecific antibodies set to disrupt the non-Hodgkin lymphoma treatment algorithm
In what settings do KOLs expect bispecific antibodies such as Roche's Lunsumio and Columvi, and Genmab/AbbVie's Epkinly, to deliver value? What impact will they have on the current treatment algorithm? What factors lead experts to say Lilly's non-covalent BTK inhibitor Jaypirca is a critical advance for patients with mantle cell lymphoma? KOLs critically assess the prospects of launched and pipeline therapies in the complex NHL sector.
In addition to the full report, licensed users can access the following KOL Bulletins via the Attachments area.
- 18 Sep 2023 KOL Bulletin -- Expert perspective on EC approval of Roche's bispecific Columvi for DLBCL
- 19 Sep 2023 KOL Bulletin -- Views on data from the TRANSCEND FL trial of BMS' CAR-T Breyanzi
Table of Contents
Executive summary (12)
Current and future treatment algorithms
Research objectives (4)
CAR T-cell therapies (31)
- Diffuse large B-cell lymphoma (11)
- Yescarta (axicabtagene ciloleucel; Gilead), Kymriah (tisagenlecleucel; Novartis) and Breyanzi (lisocabtagene maraleucel; BMS) (11)
- Follicular lymphoma (8)
- Yescarta (axicabtagene ciloleucel; Gilead), Kymriah (tisagenlecleucel; Novartis) and Breyanzi (lisocabtagene maraleucel; BMS) (8)
- Mantle cell lymphoma (7)
- Tecartus (brexucabtagene autoleucel; Gilead) and Breyanzi (lisocabtagene maraleucel; BMS) (7)
- Next-generation CAR T-cell therapies (5)
- Key insights summary (5)
T cell-engaging bispecific antibodies (BsAbs) (21)
- Approved/pipeline drugs (21)
- Lunsumio (mosunetuzumab; Roche), Epkinly/Tepkinly (epcoritamab; Genmab/AbbVie), Columvi (glofitamab; Roche) and odronextamab (Regeneron) (21)
Antibody-drug conjugates (ADCs) (24)
- Approved drugs (17)
- Polivy (polatuzumab vedotin; Roche) (9)
- Zynlonta (loncastuximab tesirine; ADC Therapeutics/Sobi) (8)
- Pipeline drugs (7)
- Adcetris (brentuximab vedotin; Seagen/Takeda) (7)
Monoclonal antibodies (mAbs) (8)
- Approved drugs (8)
- Monjuvi/Minjuvi (tafasitamab; Incyte/MorphoSys) (8)
Bcl-2 inhibitors (6)
- Pipeline drugs (6)
- Venclexta/Venclyxto (venetoclax; AbbVie/Roche) (6)
BTK inhibitors (13)
- Approved drugs (13)
- Brukinsa (zanubrutinib; BeiGene), Calquence (acalabrutinib; AstraZeneca), Imbruvica (ibrutinib; Janssen/Pharmacyclics) and Jaypirca (pirtobrutinib; Lilly) (13)
Future treatment trends (4)
- Key insights summary (4)
Appendix (4)
- KOL details (4)
- KOLs from the US (1)
- KOLs from Europe (2)
KOL Bulletins (3)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.